Merck & Co., Inc. (NYSE:MRK) declared a quarterly dividend on Tuesday, July 23rd, RTT News reports. Shareholders of record on Monday, September 16th will be given a dividend of 0.55 per share on Monday, October 7th. This represents a $2.20 dividend on an annualized basis and a yield of 2.69%. The ex-dividend date of this dividend is Friday, September 13th.
Merck & Co., Inc. has raised its dividend by an average of 2.2% annually over the last three years and has raised its dividend annually for the last 7 consecutive years. Merck & Co., Inc. has a dividend payout ratio of 51.5% indicating that its dividend is sufficiently covered by earnings. Analysts expect Merck & Co., Inc. to earn $5.35 per share next year, which means the company should continue to be able to cover its $2.20 annual dividend with an expected future payout ratio of 41.1%.
Shares of NYSE MRK opened at $81.69 on Wednesday. The firm has a market capitalization of $213.71 billion, a PE ratio of 18.82, a price-to-earnings-growth ratio of 1.70 and a beta of 0.53. The company has a current ratio of 1.21, a quick ratio of 0.92 and a debt-to-equity ratio of 0.82. Merck & Co., Inc. has a 1 year low of $66.10 and a 1 year high of $87.35. The firm’s 50-day moving average is $84.74 and its 200-day moving average is $81.87.
Merck & Co., Inc. (NYSE:MRK) last posted its quarterly earnings results on Tuesday, July 30th. The company reported $1.30 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.16 by $0.14. The business had revenue of $11.76 billion during the quarter, compared to the consensus estimate of $10.94 billion. Merck & Co., Inc. had a net margin of 21.10% and a return on equity of 43.34%. Merck & Co., Inc.’s revenue for the quarter was up 12.4% compared to the same quarter last year. During the same period in the previous year, the firm posted $1.06 earnings per share. As a group, equities research analysts anticipate that Merck & Co., Inc. will post 4.91 earnings per share for the current fiscal year.
A number of brokerages have issued reports on MRK. Bank of America set a $97.00 price objective on shares of Merck & Co., Inc. and gave the company a “buy” rating in a research note on Thursday, July 11th. Credit Suisse Group reiterated a “buy” rating and set a $95.00 target price on shares of Merck & Co., Inc. in a research report on Wednesday, August 7th. Societe Generale set a $105.00 price target on Merck & Co., Inc. and gave the stock a “buy” rating in a research report on Tuesday, September 3rd. Goldman Sachs Group began coverage on Merck & Co., Inc. in a research report on Tuesday, May 28th. They issued a “neutral” rating and a $85.00 price target on the stock. Finally, Mizuho reaffirmed a “buy” rating and set a $97.00 price objective on shares of Merck & Co., Inc. in a research note on Sunday. Three equities research analysts have rated the stock with a hold rating and eighteen have given a buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus target price of $93.29.
In related news, CFO Robert M. Davis sold 216,718 shares of the company’s stock in a transaction on Tuesday, June 25th. The shares were sold at an average price of $85.43, for a total value of $18,514,218.74. Following the completion of the sale, the chief financial officer now owns 354,378 shares in the company, valued at approximately $30,274,512.54. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, EVP Richard R. Deluca sold 6,427 shares of the firm’s stock in a transaction on Friday, August 9th. The stock was sold at an average price of $85.09, for a total value of $546,873.43. Following the sale, the executive vice president now directly owns 103,223 shares in the company, valued at approximately $8,783,245.07. The disclosure for this sale can be found here. 0.27% of the stock is owned by insiders.
About Merck & Co., Inc.
Merck & Co, Inc provides healthcare solutions worldwide. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The company offers therapeutic and preventive agents to treat cardiovascular, type 2 diabetes, chronic hepatitis C virus, HIV-1 infection, intra-abdominal, fungal infection, insomnia, and inflammatory diseases.
Read More: What does a hold rating mean?
Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.